Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B

다국어 초록 (Multilingual Abstract)

Background: Besifovir dipivoxil maleate (BSV) with L-carnitine is the first-line antiviral agent for chronic hepatitis B (CHB) infection. We investigated whether BSV combined with L-carnitine improves hepatic steatosis (HS).
Methods: Treatment-naïve patients with CHB who were initiated on antiviral therapy (AVT) were enrolled. The magnitude of HS was assessed using hepatic steatosis index (HSI), and HS improvement was defined as a ≥ 10% reduction in the HSI score from the baseline.
Results: The mean age of the study patients was 56 years with a male predominance (n = 178, 64.7%). The mean body mass index (BMI), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count were 23.5 kg/m2 , 49.6 IU/L, 49.0 IU/L, and 191.3 × 109 /L, respectively. The mean HSI and fibrosis (FIB)-4 index were 32.6 and 0.5, respectively.
After 6 months of AVT, platelet count (mean, 191.3→167.0 × 109 /L), fasting glucose (mean, 113.1→105.9 mg/dL), AST (mean, 49.6→28.0 IU/L), ALT (mean, 49.0→33.9 IU/L), and total cholesterol (mean, 170.0→162.1 mg/dL) levels significantly decreased (all P < 0.05). In the BSV group, AST (mean, 95.2→30.2 IU/L) and ALT (mean, 81.1→31.1 IU/L) levels significantly reduced (all P < 0.05), whereas HSI and FIB-4 index were maintained (all P > 0.05). In the univariate analysis, age, BMI, diabetes, cirrhosis, fasting glucose level, and ALT were significantly associated with HS improvement (all P < 0.05).
Conclusion: BSV with L-carnitine did not show any improvement of HS in patients with CHB. Further prospective randomized controlled studies are needed to validate the potential beneficial effects of BSV with L-carnitine in CHB infection.

참고문헌 (Reference)

1 Yuen MF, "Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir : results from a multicentre study" 62 (62): 526-532, 2015

2 Yuen MF, "Treatment of chronic hepatitis B" 1 (1): 232-241, 2001

3 주덕윤, "The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults" 대한간학회 19 (19): 140-147, 2013

4 한광협, "The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter" 연세대학교의과대학 57 (57): 885-892, 2016

5 Lai CL, "Phase IIb multicentred randomised trial of besifovir(LB80380)versus entecavir in Asian patients with chronic hepatitis B" 63 (63): 996-1004, 2014

6 Yuen MF, "Pharmacokinetics of LB80331 and LB80317following oral administration of LB80380, a new antiviral agent for chronic hepatitis B(CHB), in healthy adult subjects, CHB patients, and mice" 53 (53): 1779-1785, 2009

7 Haga Y, "Nonalcoholic fatty liver disease and hepatic cirrhosis : comparison with viral hepatitis-associated steatosis" 21 (21): 12989-12995, 2015

8 Angulo P, "Nonalcoholic fatty liver disease" 346 (346): 1221-1231, 2002

9 Fan JG, "New trends on obesity and NAFLD in Asia" 67 (67): 862-873, 2017

10 Wong GL, "Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B" 58 (58): 111-117, 2009

11 Cheng JY, "Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B" 64 (64): 1507-1517, 2016

12 Ishikawa H, "L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway" 9 (9): e100627-, 2014

13 Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B" 대한간학회 25 (25): 93-159, 2019

14 David Sooik Kim, "Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir" 대한간학회 25 (25): 283-293, 2019

15 Huh JH, "High dietary sodium intake assessed by estimated 24-h urinary sodium excretion is associated with NAFLD and hepatic fibrosis" 10 (10): e0143222-, 2015

16 Fattovich G, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors" 127 (127): S35-S50, 2004

17 Wang B, "Hepatitis B virus infection is not associated with fatty liver disease : Evidence from a cohort study and functional analysis" 19 (19): 320-326, 2019

18 Wang MM, "Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors" 59 (59): 2571-2579, 2014

19 Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease" 42 (42): 503-508, 2010

20 Machado MV, "Hepatic steatosis in hepatitis B virus infected patients : meta-analysis of risk factors and comparison with hepatitis C infected patients" 26 (26): 1361-1367, 2011

21 Fujisawa K, "Evaluation of the effects of L-carnitine on medaka(Oryzias latipes)fatty liver" 7 (7): 2749-, 2017

22 전대원, "Efficacy and safety of entecavir plus carnitine complex (GODEXⓇ) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study" 대한간학회 19 (19): 165-172, 2013

23 Lampertico P, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection" 67 (67): 370-398, 2017

24 Zhang Z, "Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection" 6 (6): 32875-, 2016

25 Zhang Z, "Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection" 6 (6): 32875-, 2016

26 Kahl S, "Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance" 9 (9): e94059-, 2014

27 Kahl S, "Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance" 9 (9): e94059-, 2014

28 Nishikawa H, "Comparison of FIB-4index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir" 8 (8): 152-161, 2017

29 Chang Y, "Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population" 108 (108): 1861-1868, 2013

30 Lai CL, "Chronic hepatitis B--new goals, new treatment" 359 (359): 2488-2491, 2008

31 Seto WK, "Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B" 16 (16): 575-583.e2, 2018

32 Brown RS Jr, "Antiviral therapy in chronic hepatitis B viral infection during pregnancy : a systematic review and meta-analysis" 63 (63): 319-333, 2016

33 Yuen MF, "Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease" 51 (51): 767-776, 2010

34 Yuen MF, "A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B" 11 (11): 977-983, 2006